Hosted on MSN10d
Boston Scientific sees success in PFA device trialUS healthtech giant Boston Scientific’s pulmonary vein isolation (PVI) device trial has met its primary endpoint in patients ...
Zacks.com on MSN11d
BSX Stock Rises on Positive Data Announcement at the AF SymposiumBoston Scientific Corporation BSX recently presented data supporting the use of the FARAPULSE Pulsed Field Ablation (“PFA”) ...
The results will support the company’s application for expanded labeling of its popular Farapulse pulsed field ablation ...
Morgan Stanley analyst Patrick Wood maintained a Buy rating on Boston Scientific (BSX – Research Report) today and set a price target of ...
Nanosecond PFA 360° Cardiac Catheter for AF ablation to be highlighted in late-breaking clinical science session and in a live case transmission MIAMI, January 13, 2025--(BUSINESS WIRE)--Pulse ...
The feasibility study is intended to assess the initial safety and efficacy of the Nanosecond PFA 360° Cardiac Catheter System for the treatment of AF (NCT06696170). To date, 77 patients have ...
The ADVANTAGE AF study examined the use of the FARAPULSE PFA System for PVI and posterior wall ablation (PWA) in patients with persistent AF — an irregular or rapid heartbeat that lasts longer ...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results